| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790159 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
The use of cPN in patients with mRCC is increasing. cPN is associated with improved OS in patients with mRCC, although this effect is limited to patients with primary tumors<4Â cm.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Andrew T. M.D., M.S., Amirali H. M.D., Nicholas M. M.D., Izak M.D., David C. M.D., Alexandra M.D., Ph.D., Kiran M.D., Jeremy M.D., Arie S. M.D., Allan J. M.D., M.S., Karim M.D., M.S.H.S.,